艾伯维公司高管近日透露,预计到2026年,其明星产品Skyrizi的年收入将攀升至215亿美元,而同为重磅药物的Rinvoq也将实现101亿美元的营收目标。这一预测凸显了公司对这两款免疫疾病治疗药物市场前景的强烈信心。
随着全球自身免疫疾病患者群体的持续扩大,Skyrizi和Rinvoq凭借卓越的临床疗效,正逐步成为细分领域的领军产品。分析指出,若能达到预期目标,这两款药物将共同构筑艾伯维未来业绩增长的双引擎,有效抵消明星修美乐专利到期后带来的收入压力。
艾伯维公司高管近日透露,预计到2026年,其明星产品Skyrizi的年收入将攀升至215亿美元,而同为重磅药物的Rinvoq也将实现101亿美元的营收目标。这一预测凸显了公司对这两款免疫疾病治疗药物市场前景的强烈信心。
随着全球自身免疫疾病患者群体的持续扩大,Skyrizi和Rinvoq凭借卓越的临床疗效,正逐步成为细分领域的领军产品。分析指出,若能达到预期目标,这两款药物将共同构筑艾伯维未来业绩增长的双引擎,有效抵消明星修美乐专利到期后带来的收入压力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.